Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2027 Earnings Guidance

Posted by Stanley Muller on Aug 6th, 2026

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 4.550-4.650 for the period, compared to the consensus EPS estimate of 4.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $53.13 on Thursday. The stock’s 50-day moving average price is $48.55 and its two-hundred day moving average price is $56.14. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $75.31. The stock has a market cap of $2.52 billion, a P/E ratio of 13.59, a price-to-earnings-growth ratio of 1.67 and a beta of 0.34. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.10. The company had revenue of $265.71 million for the quarter, compared to analyst estimates of $250.34 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities analysts predict that Prestige Consumer Healthcare will post 4.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on PBH shares. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $70.75.

Check Out Our Latest Report on Prestige Consumer Healthcare

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently bought and sold shares of PBH. UMB Bank n.a. raised its holdings in Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. Danske Bank A S acquired a new position in Prestige Consumer Healthcare during the 3rd quarter worth about $37,000. Brown Brothers Harriman & Co. bought a new position in shares of Prestige Consumer Healthcare during the third quarter worth about $44,000. Finally, CIBC Private Wealth Group LLC increased its position in Prestige Consumer Healthcare by 142.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after purchasing an additional 647 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

Earnings History and Estimates for Prestige Consumer Healthcare (NYSE:PBH)

Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.